DRI's scientists found that the key pathophysiology of neurodegenerative and neurodevelopmental disorders is the result of a common neurochemical imbalance. The genes encoding the activities of these pathways are implicated in the aging process and affected by human environmental interactions. DRI also discovered objective blood-based proprietary biomarkers to match patients with precise interventions.
DRI has identified a novel combination of readily available drugs approved for other indications that can restore the balance and has conducted animal studies showing that the restored balance can normalize behavior, protein expressions, and related physiological alterations that restore patients to a healthy life. 
While human clinical studies using this novel combination of readily available drugs will initially provide quick and inexpensive validation for humans afflicted with Frontotemporal Dementia (FTD), an orphan condition suffered by actor Bruce Willis that shares a pathophysiological mechanism with other age-related neurodegenerative disorders including Alzheimer's, and Fragile X Autism (FXS), an orphan condition that shares pathophysiological conditions with Autism Spectrum Disorder (ASD), DRI also has developed a novel, safe, well tolerated "first-in-class" drug candidate with the potential to benefit a wide spectrum of more complicated dementia and ASD conditions to follow.